// App-Quantinova.ai

5071 : The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.

Researchers

Presenter

  • Andrew J. Armstrong

Principal Investigators

  • Taro Iguchi

  • Arun Azad

  • Arnauld Villers

  • Boris Alekseev

  • Daniel P. Petrylak

  • Russell Zelig Szmulewitz

  • Antonio Alcaraz

  • Neal D. Shore

  • Jeffrey Holzbeierlein

  • Francisco Gomez-Veiga

  • Brad Rosbrook

  • Fabian Zohren

  • Gabriel P. Haas

  • Georgia Gourgioti

  • Nader N. El-Chaar

  • Arnulf Stenzl

Medical Centers

  • Duke Cancer Institute Center for Prostate & Urologic Cancers, Duke University, Durham, NC, Osaka City University Graduate School of Medicine, Osaka, Japan

  • Monash Health, Melbourne, Australia

  • University Hospital Centre, Lille University, Lille, France

  • P.A. Herzen Moscow Cancer Research Institute, Moscow, Russia

  • Yale Cancer Center, New Haven, CT, The University of Chicago, Chicago, IL

  • Hospital Clinic Barcelona, Barcelona, Spain

  • Carolina Urologic Research Center, Myrtle Beach, SC, The University of Kansas Medical Center, Kansas City, KS, Hospital Universitario de Salamanca, GITUR-IBSAL, Salamanca, Spain

  • Pfizer Inc, San Diego, CA

  • Astellas Pharma, Inc., Northbrook, IL

  • Astellas Pharma Inc., London, United Kingdom

  • University Hospital, Eberhard Karls University, Tübingen, Germany

Locations

  • Japan

  • Australia

  • France

  • Russia

  • Spain

  • United Kingdom

  • Germany

Companies

  • PharmAbcine Inc.

  • Astellas Pharma Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

  • Bone metastases

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • Enzalutamide

  • Docetaxel

  • Androgen Tear

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • N/A

Study Id's

  • NCT02677896

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved